Clinical Trial Update: Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating penpulimab combined with anlotinib as neoadjuvant therapy for resectable non-small cell lung cancer is ongoing, status curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Penpulimab

Snippet

Sponsor: Tang-Du Hospital | Conditions: NSCLC | Phase 4 | Status: UNKNOWN